BioSpace News Archive

Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for rare genetic diseases, today announced that it has entered into a worldwide exclusive licensing agreement with Rescue Hearing Inc. (RHI) to develop a novel gene therapy for DFNB8 genetic hearing loss.

ProgenaCare Global ™ LLC., the developer and manufacturer of the only human keratin matrix, ProgenaMatrix®, approved for use in acute and chronic wounds, has announced the addition of Howard Walthall as Chief Executive Officer.

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2022 financial results after market close on Thursday, May 26, 2022.

Leica Biosystems is launching BOND-PRIME, a premium Advanced Staining solution, to advance diagnostic productivity in the lab.

The global Virtual Clinical Trials market size is estimated to reach around US$ 21.5 billion by 2030 from valued at US$ 8.4 billion in 2020, growing at a CAGR of 6.7% over the forecast period 2021 to 2030.

The global endoscopy devices market size is estimated to surpass around US$ 72.9 billion by 2030 and it is expected to grow at a CAGR of 9.3% over the forecast period 2021 to 2030.

According to Report, the Clinical Trial Supplies market size is estimated to surpass around US$ 13.3 billion by 2030 and is expected to registered growth at a CAGR of 17.3% from 2021 to 2030.

Roivant Sciences will participate in four upcoming healthcare investor conferences.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright Global Life Science Conference May 23-26, 2022.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.